Intracoronary recombinant tissue-type plasminogen activator (rt-PA)

Coronary Artery Disease

Volumn 7, Issue 9, 1996, Pages 637-640

  Tiefenbrunn, Alan J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

intracoronary rt PA; intracoronary thrombolysis; myocardial infarction; thrombolysis

Indexed keywords

ALTEPLASE;

ACUTE HEART INFARCTION; FIBRINOLYTIC THERAPY; HUMAN; INTRACORONARY INFUSION; PRIORITY JOURNAL; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT PLANNING;

EID: 0029989944     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199609000-00004     Document Type: Review

References (27)

1. Tiefenbrunn AJ: Clinical benefits of thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1992, 69:3A-11A. Concise review of the information documenting the clinical benefits of reperfusion therapy in patients with evolving myocardial infarction.
2. Goldhaber SZ, Kessler CM, Heit J, Markis J, Sharma GVRK, Dawley D, et al.: A randomized controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 1988, ii:293-298.
3. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995, 333:1581-1587. A pivotal study documenting improvement in morbidity in patients receiving intravenous tPA within 3 h of onset of symptoms of embolic stroke. This study was largely responsible for approval by the Food and Drug Administration of rt-PA for this indication in June 1996.
4. Tiefenbrunn AJ, Sobel BE: Factors contributing to the emergence of coronary thrombolysis. In Thrombolysis and the Heart. Edited by Sobel BE. Philadelphia: WB Saunders Co; 1987:49-53.
5. Salinger MH, Lopez A, Frohlich TG, McDonough TJ, Hueter DC, Stagl RD: Systemic and local saphenous vein graft thrombolysis using a tissue plasminogen activator. Cathet Cardiovasc Diagn 1990, 19:198-201.
6. Denardo SJ, Teirstein PS: Urokinase infusion and stenting of older saphenous vein grafts. J Inv Cardiol 1995, 7 (suppl E):26E-35E.
7. Collen D, Topol FJ, Tiefenbrunn AJ, Gold HK, Weisfeldt ML, Sobel BE, et al.: Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. Circulation 1984, 70:1012-1017. The first report of the use of recombinant tPA in patients. Double-chain rt-PA was very effective for promptly inducing angiographically documented thrombolysis, whether administered by the intracoronary or the intravenous route.
8. Garabedian HD, Gold HK, Leinbach RC, Johns JA, Yasuda T, Kankae M, Collen D: Comparative properties of two clinical preparations of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. J Am Coll Cardiol 1987, 9:599-607.
9. Rijken DC, Hoylaerts M, Collen D: Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator. J Biol Chem 1982, 257:2920-2925.
10. Samaha JK, Quigley P, Kereiakes DJ, Griffin B, Stack RS, Sigmon K, et al.: Intracoronary thrombolytic therapy in patients with refractory thrombus after intravenous treatment [abstract]. J Am Coll Cardiol 1989, 13:92A.
11. Neuhaus KL, Tebbe U, Gottwik M, Weber MAJ, Feuerer W, Niederer W, et al.: Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS). J Am Coll Cardiol 1988, 12:581-587.
12. Arora RR, Platko WP, Bhadwar K, Simpfendorfer C: Role of intracoronary thrombus in acute complications during percutaneous transluminal coronary angioplasty. Cathet Cardiovasc Diagn 1989, 16:226-229.
13. Goldbaum T, DiSciascio G, Cowley MJ, Vetrovec GW: Early occlusion following successful coronary angioplasty: clinical and angiographic observations. Cathet Cardiovasc Diagn 1989, 17:22-27.
14. Mabin TA, Holmes DR, Smith HC, Vlietstra RE, Bove AA, Reeder GS, et al.: Intracoronary thrombus: role in coronary occlusion complicating percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1985, 5:198-202.
15. Tiefenbrunn JA: Tissue-type plasminogen activator: intracoronary applications. Cathet Cardiovasc Diagn 1990, 19:108-115.
16. Grill HP, Brinker JA: Nonacute thrombolytic therapy: an adjunct to coronary angioplasty in patients with large intravascular thrombi. Am Heart J 1989, 118:662-667.
17. Ambrose JA, Almeida OD, Sharma S, Torre SR, Marmur JD, Israel DH, et al. for the TAUSA Investigators: Adjunctive thrombolytic therapy during angioplasty for ischemic rest angina: results of the TAUSA trial. Circulation 1994, 90:69-77. Report of a major randomized trial of adjunctive intracoronary urokinase in patients undergoing elective angioplasty. Urokinase did not decrease the rate of abrupt closure but patients with visible thrombus before angioplasty were excluded from randomization.
18. Topol EJ, Califf RM, George BS, Kereiakes DJ, Rothbaum D, Candela RJ, et al.: Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction. Circulation 1988, 77:1100-1107.
19. Topol EJ: Coronary angioplasty for acute myocardial infarction. Ann Intern Med 1988, 109:970-980.
20. The GUSTO Angiographic Investigators: The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function and survival after acute myocardial infarction. N Engl J Med 1993, 329:1615-1622. Report of over 41 000 patients receiving thrombolytic therapy for acute myocardial infarction which documents acceptable safety and low mortality in all treatment groups, with the lowest mortality observed in patients receiving intravenous rt-PA.
21. DiSciascio G, Kohli RS, Goudreau E, Sabri N, Vetrovec GW: Intracoronary recombinant tissue-type plasminogen activator in unstable angina: a pilot angiographic study. Am Heart J 1991, 122:1-6.
22. Waller BF, Rothbaum DA, Pinkerton CA, Cowley MJ, Linnemeier TJ, Orr C, et al.: Status of the myocardium and infarct-related coronary artery in 19 necropsy patients with acute recanalization using pharmacologic (streptokinase, r-tissue plasminogen activator), mechanical (percutaneous transluminal coronary angioplasty) or combined types of reperfusion therapy. J Am Coll Cardiol 1987, 9:785-801.
23. Gulba D, Daniel WG, Simon R, Jost S, Barthels M, Amende WO, et al.: Role of thrombolysis and thrombin in patients with acute coronary occlusion during percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1990, 16:563-568.
24. Ruocco NA, Currier JW, Jacobs AK, Ryan TJ, Faxon DP: Experience with low-dose intracoronary recombinant tissue-type plasminogen activator for nonacute total occlusions before percutaneous transluminal coronary angioplasty. Am J Cardiol 1991, 68:1609-1613.
25. Tiefenbrunn AJ: Intracoronary thrombolysis. Chest 1992, 101:1484-1486.
26. Gu S, Ducas J, Patton JN, Greenberg D, Prewitt RM: Coronary thrombolysis: comparative effects of intracoronary administration of recombinant tissue plasminogen activator and urokinase. Chest 1992, 101:1684-1690. An animal study comparing intracoronary rt-PA with intracoronary urokinase at different dose levels. One of very few studies directly comparing thrombolytic efficacy between different agents.
27. Gore JM, Sloan M, Price TR, Randall AM, Bovill E, Collen D, et al.: Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction study. Circulation 1991, 83:448-459.